{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:29:40Z","timestamp":1764883780670,"version":"3.46.0"},"reference-count":52,"publisher":"BMJ","issue":"11","license":[{"start":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T00:00:00Z","timestamp":1762300800000},"content-version":"unspecified","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["1R61DA057675-01","U24DA057612"],"award-info":[{"award-number":["1R61DA057675-01","U24DA057612"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Open"],"accepted":{"date-parts":[[2025,10,2]]},"published-print":{"date-parts":[[2025,11]]},"abstract":"\n Introduction<\/jats:title>\n \n Despite the continued burden of opioid overdose in communities in the USA, effective treatments for opioid use disorder (OUD), such as medication for opioid use disorder (MOUD), remain underused. Motivational interviewing techniques and linkage to MOUD via digital health are innovative practices developed to overcome persistent barriers to accessing MOUD treatment. These practices are merged in a comprehensive digital health platform,\n RecoveryPad<\/jats:italic>\n (developed by the Center for Progressive Recovery). Our study, \u2018Using System Dynamics Modeling to Foster Real-time Connections to Care\u2019 (NIH Award #: 1R61DA057675-01), is a pilot to assess the feasibility and behaviour change potential of\n RecoveryPad<\/jats:italic>\n for our target audience of people experiencing OUD.\n <\/jats:p>\n <\/jats:sec>\n \n Methods and analysis<\/jats:title>\n \n This study will recruit 40 participants in Connecticut and New York through online platforms, such as social media and digital advertising, and direct access via quick-response (QR) codes distributed by local community partners. Eligibility assessment and enrolment will be conducted virtually. Individuals reporting symptoms indicating moderate to severe OUD who are at least 18 years of age are eligible for the study, excluding those who are currently receiving MOUD, pregnant or incarcerated. Enrolled participants will interact with an automated chatbot, live recovery coaches and, if desired, be referred to a telehealth MOUD provider via the\n RecoveryPad<\/jats:italic>\n platform. Participants will have access to the platform for 30 days and will be asked to complete brief surveys to assess MOUD engagement and secondary outcomes at 30 and 90 days. Additionally, system dynamics (SD) models will be developed at the individual level to simulate participant interactions with\n RecoveryPad<\/jats:italic>\n , and at the community level to improve understanding of the systems affecting OUD and MOUD access.\n <\/jats:p>\n <\/jats:sec>\n \n Ethics and dissemination<\/jats:title>\n This project received approval from the Yale University Human Investigation Committee in 2024 (HIC # 2000034414). All participants will complete an electronic consent form with detailed study information and release of information to obtain data related to MOUD appointment attendance. Findings and conclusions from this pilot will be disseminated via peer-reviewed publication, advisory board meetings and meetings with community partners.<\/jats:p>\n <\/jats:sec>\n \n Trial registration number<\/jats:title>\n \n NCT05832879<\/jats:ext-link>\n .\n <\/jats:p>\n <\/jats:sec>","DOI":"10.1136\/bmjopen-2025-102796","type":"journal-article","created":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T06:55:51Z","timestamp":1762325751000},"page":"e102796","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Increasing timely access to evidence-based treatment for opioid use disorder using novel digital health and system dynamics modelling approaches: a study protocol"],"prefix":"10.1136","volume":"15","clinical-trial-number":[{"clinical-trial-number":"nct05832879","registry":"10.18810\/clinical-trials-gov"}],"author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-2648-4840","authenticated-orcid":false,"given":"Turner","family":"Canty","sequence":"first","affiliation":[{"name":"Center for Systems and Community Design, CUNY Graduate School of Public Health & Health Policy, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8027-8779","authenticated-orcid":false,"given":"Nasim","family":"S Sabounchi","sequence":"additional","affiliation":[{"name":"Center for Systems and Community Design, CUNY Graduate School of Public Health & Health Policy, New York, New York, USA"},{"name":"Health Policy and Management, CUNY Graduate School of Public Health & Health Policy, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Robert","family":"Heimer","sequence":"additional","affiliation":[{"name":"Department of Epidemiology of Microbial Diseases, Yale University School of Public Health, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pantalon","sequence":"additional","affiliation":[{"name":"School of Health Professions, Long Island University, Brookville, New York, USA"},{"name":"Center for Progressive Recovery, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caitlin","family":"Ryus","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laurel","family":"Buchanan","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mikas","family":"Grewal","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Justine","family":"Maffei","sequence":"additional","affiliation":[{"name":"Center for Systems and Community Design, CUNY Graduate School of Public Health & Health Policy, New York, New York, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gail","family":"D\u2019Onofrio","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Chronic Disease Epidemiology, Yale University School of Public Health, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebekah","family":"Heckmann","sequence":"additional","affiliation":[{"name":"Department of Emergency Medicine, Yale University School of Medicine, New Haven, Connecticut, USA"},{"name":"Department of Anesthesiology, Yale University School of Medicine, New Haven, CT, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2025,11,4]]},"reference":[{"key":"2025120413253228000_15.11.e102796.1","unstructured":"Connecticut Public Health . Fatal unintentional and undetermined intent drug overdose report. Connecticut; 2025. Available: https:\/\/portal.ct.gov\/-\/media\/dph\/injury-and-violence-prevention\/opioid-overdose-data\/monthly-death-reports\/2019-january-2025_drug-overdose-deaths-monthly-report_connecticut_2-25-2025-final.pdf [accessed 15 Mar 2025]"},{"key":"2025120413253228000_15.11.e102796.2","article-title":"Public health implications of recent declines in fatal drug overdoses in New York State and the United States","volume":"2","author":"Holtgrave","year":"2024","journal-title":"Health Aff Sch"},{"key":"2025120413253228000_15.11.e102796.3","doi-asserted-by":"publisher","DOI":"10.1016\/j.jsat.2021.108449"},{"key":"2025120413253228000_15.11.e102796.4","unstructured":"Substance Abuse and Mental Health Services Administration . Methadone take-home flexibilities extension guidance, 2024. Available: https:\/\/www.samhsa.gov\/medications-substance-use-disorders\/statutes-regulations-guidelines\/methadone-guidance [Accessed 15 Apr 2023]."},{"key":"2025120413253228000_15.11.e102796.5","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2015.3474"},{"key":"2025120413253228000_15.11.e102796.6","first-page":"26","article-title":"Extending pandemic flexibilities for opioid use disorder treatment: authorities and methods","volume":"106","author":"Dooling","year":"2021","journal-title":"Minn Law Rev"},{"key":"2025120413253228000_15.11.e102796.7","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2024.20702","article-title":"Extended-Release 7-Day Injectable Buprenorphine for Patients With Minimal to Mild Opioid Withdrawal","volume":"7","author":"D\u2019Onofrio","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2025120413253228000_15.11.e102796.8","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1097\/ADM.0000000000000934","article-title":"Low-threshold Buprenorphine Treatment in a Syringe Services Program: Program Description and Outcomes","volume":"16","author":"Jakubowski","year":"2022","journal-title":"J Addict Med"},{"key":"2025120413253228000_15.11.e102796.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2023.111040"},{"key":"2025120413253228000_15.11.e102796.10","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.20622","article-title":"Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder","volume":"3","author":"Wakeman","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2025120413253228000_15.11.e102796.11","unstructured":"Navarretta N . Hartford, Connecticut: Department of Mental Health and Addiction Services. State of Connecticut Department of Mental Health and Addiction Services triennial state substance use plan, Available: https:\/\/portal.ct.gov\/-\/media\/dmhas\/eqmi\/2022-triennial-report-final.pdf [Accessed 23 Jan 2025]."},{"key":"2025120413253228000_15.11.e102796.12","unstructured":"U.S. Food and Drug Administration . What is digital health?, 2020. Available: https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/what-digital-health [Accessed 23 Jan 2025]."},{"key":"2025120413253228000_15.11.e102796.13","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1001\/jamainternmed.2018.7700","article-title":"Racial Differences in Opioid Overdose Deaths in New York City, 2017","volume":"179","author":"Allen","year":"2019","journal-title":"JAMA Intern Med"},{"key":"2025120413253228000_15.11.e102796.14","doi-asserted-by":"crossref","DOI":"10.1016\/j.dadr.2022.100029","article-title":"The opioid epidemic among the Latino population in California","volume":"2","author":"Valdez","year":"2022","journal-title":"Drug Alcohol Depend Rep"},{"key":"2025120413253228000_15.11.e102796.15","doi-asserted-by":"publisher","DOI":"10.1377\/hlthaff.2020.02261"},{"key":"2025120413253228000_15.11.e102796.16","unstructured":"Substance Abuse and Mental Health Services Administration National Mental Health and Substance Use Policy Laboratory . Telehealth for the treatment of serious mental illness and substance use disorders, 2021. Available: https:\/\/store.samhsa.gov\/sites\/default\/files\/pep21-06-02-001.pdf [Accessed 15 Apr 2024]."},{"key":"2025120413253228000_15.11.e102796.17","unstructured":"Substance Abuse and Mental Health Services Administration . Screening, brief intervention, and referral to treatment (SBIRT), 2024. Available: https:\/\/www.samhsa.gov\/sbirt [Accessed 23 Jan 2025]."},{"key":"2025120413253228000_15.11.e102796.18","article-title":"Access to medication for opioid use disorder supported by telemedicine and healthcare coverage: A web-based survey during the COVID-19 pandemic","volume":"18","author":"Monnig","year":"2023","journal-title":"Addict Behav Rep"},{"key":"2025120413253228000_15.11.e102796.19","doi-asserted-by":"crossref","DOI":"10.1177\/21501319241233198","article-title":"Access to MAT: Participants\u2019 Experiences With Transportation, Non-Emergency Transportation, and Telehealth","volume":"15","author":"Boyd","year":"2024","journal-title":"J Prim Care Community Health"},{"key":"2025120413253228000_15.11.e102796.20","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/ADM.0000000000001006","article-title":"Perspectives of Patients Receiving Telemedicine Services for Opioid Use Disorder Treatment: A Qualitative Analysis of User Experiences","volume":"16","author":"Sousa","year":"2022","journal-title":"J Addict Med"},{"key":"2025120413253228000_15.11.e102796.21","unstructured":"Telehealth.hhs.gov . Telehealth for behavioral health care, 2023. Available: https:\/\/telehealth.hhs.gov\/providers\/best-practice-guides\/telehealth-for-behavioral-health\/tele-treatment-for-substance-use-disorders [Accessed 23 Jan 2025]."},{"key":"2025120413253228000_15.11.e102796.22","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyt.2024.1351816","article-title":"Old tech but not low tech: telephone-based treatment provision for substance use","volume":"15","author":"Walton","year":"2024","journal-title":"Front Psychiatry"},{"key":"2025120413253228000_15.11.e102796.23","doi-asserted-by":"crossref","unstructured":"Guillen AG , Reddy M , Saadat S , et al . Utilization of Telehealth Solutions for Patients with Opioid Use Disorder Using Buprenorphine: A Scoping Review. Telemedicine and E-Health 2021.:tmj.2021.0308. doi:10.1089\/tmj.2021.0308","DOI":"10.1089\/tmj.2021.0308"},{"key":"2025120413253228000_15.11.e102796.24","doi-asserted-by":"crossref","unstructured":"DiClemente CC . Screening, brief intervention, and referral to treatment: an efficacious public health approach to substance use prevention and treatment. In: Cimini MD , Martin JL , eds. Screen. Brief Interv. Ref. Treat. Subst. Use Pract. Guide, Washington: American Psychological Association, 2020: 9\u201329. Available: https:\/\/doi.org\/10.1037\/0000199-002","DOI":"10.1037\/0000199-002"},{"key":"2025120413253228000_15.11.e102796.25","unstructured":"Substance Abuse and Mental Health Services Administration . Enhancing motivation for change in substance use disorder treatment, 2019. Available: https:\/\/store.samhsa.gov\/sites\/default\/files\/tip-35-pep19-02-01-003.pdf [Accessed 15 Apr 2024]."},{"key":"2025120413253228000_15.11.e102796.26","doi-asserted-by":"crossref","first-page":"111118","DOI":"10.1016\/j.drugalcdep.2024.111118","article-title":"A qualitative study to determine perspectives of clinicians providing telehealth opioid use disorder treatment","volume":"256","author":"Burke","year":"2024","journal-title":"Drug Alcohol Depend"},{"key":"2025120413253228000_15.11.e102796.27","doi-asserted-by":"crossref","DOI":"10.1186\/s13011-022-00483-1","article-title":"Improving equity and access to buprenorphine treatment through telemedicine at syringe services programs","volume":"17","author":"Lambdin","year":"2022","journal-title":"Subst Abuse Treat Prev Policy"},{"key":"2025120413253228000_15.11.e102796.28","doi-asserted-by":"crossref","DOI":"10.1186\/s12889-021-10669-0","article-title":"Syringe service program-based telemedicine linkage to opioid use disorder treatment: protocol for the STAMINA randomized control trial","volume":"21","author":"Watson","year":"2021","journal-title":"BMC Public Health"},{"key":"2025120413253228000_15.11.e102796.29","doi-asserted-by":"crossref","DOI":"10.1186\/s13063-023-07074-w","article-title":"Project T-SHARP: study protocol for a multi-site randomized controlled trial of tele-harm reduction for people with HIV who inject drugs","volume":"24","author":"Tookes","year":"2023","journal-title":"Trials"},{"key":"2025120413253228000_15.11.e102796.30","doi-asserted-by":"crossref","DOI":"10.2196\/43122","article-title":"A Prescription Digital Therapeutic to Support Unsupervised Buprenorphine Initiation for Patients With Opioid Use Disorder: Protocol for a Proof-of-Concept Study","volume":"12","author":"Luderer","year":"2023","journal-title":"JMIR Res Protoc"},{"key":"2025120413253228000_15.11.e102796.31","doi-asserted-by":"crossref","unstructured":"Davoust M , Bazzi AR , Blakemore S , et al . Patient and Clinician Experiences with the Implementation of Telemedicine and Related Adaptations in Office-Based Buprenorphine Treatment During the COVID-19 Pandemic: A Qualitative Study. Res Sq 2024.:rs.3.rs-4272282. doi:10.21203\/rs.3.rs-4272282\/v1","DOI":"10.21203\/rs.3.rs-4272282\/v1"},{"key":"2025120413253228000_15.11.e102796.32","doi-asserted-by":"crossref","unstructured":"American Psychiatric Association . Opioid-Related Disorders. Diagn. Stat. Man. Ment. Disord. DSM-5-TR. American Psychiatric Association Publishing, 2022:540\u20136.Available: https:\/\/doi.org\/10.1176\/appi.books.9780890425787","DOI":"10.1176\/appi.books.9780890425787"},{"key":"2025120413253228000_15.11.e102796.33","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010"},{"key":"2025120413253228000_15.11.e102796.34","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2019.103208"},{"key":"2025120413253228000_15.11.e102796.35","doi-asserted-by":"publisher","DOI":"10.1197\/j.aem.2004.10.021"},{"key":"2025120413253228000_15.11.e102796.36","unstructured":"Substance Abuse and Mental Health Services Administration . Chapter 3\u2014motivational interviewing as a counseling style. enhancing motiv. In: Change Subst Use Disord Treat Updat. Rockville, MD: Substance Abuse and Mental Health Services Administration, 2019."},{"key":"2025120413253228000_15.11.e102796.37","doi-asserted-by":"publisher","DOI":"10.1111\/j.1553-2712.2010.00824.x"},{"key":"2025120413253228000_15.11.e102796.38","unstructured":"R Core Team . R: a language and environment for statistical computing. 2024."},{"key":"2025120413253228000_15.11.e102796.39","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2005.066043"},{"key":"2025120413253228000_15.11.e102796.40","doi-asserted-by":"publisher","DOI":"10.2105\/AJPH.2005.062059"},{"key":"2025120413253228000_15.11.e102796.41","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1002\/sdr.1596","article-title":"Community and programmatic factors influencing effective use of system dynamic models","volume":"34","author":"Minyard","year":"2018","journal-title":"Syst Dyn Rev"},{"key":"2025120413253228000_15.11.e102796.42","doi-asserted-by":"publisher","DOI":"10.1080\/00952990.2021.1938100"},{"key":"2025120413253228000_15.11.e102796.43","doi-asserted-by":"crossref","unstructured":"Hovmand PS . Community Based System Dynamics. New York: Springer, 2014.","DOI":"10.1007\/978-1-4614-8763-0"},{"key":"2025120413253228000_15.11.e102796.44","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1177\/10497315221118109","article-title":"Qualitative System Dynamics Modeling to Support Community Planning in Opioid Overdose Prevention","volume":"33","author":"Sabounchi","year":"2023","journal-title":"Res Soc Work Pract"},{"key":"2025120413253228000_15.11.e102796.45","doi-asserted-by":"crossref","DOI":"10.1186\/s12961-021-00807-w","article-title":"Assessing the impact of the Good Samaritan Law in the state of Connecticut: a system dynamics approach","volume":"20","author":"Sabounchi","year":"2022","journal-title":"Health Res Policy Syst"},{"key":"2025120413253228000_15.11.e102796.46","doi-asserted-by":"crossref","DOI":"10.1186\/s12954-024-00990-3","article-title":"Using qualitative system dynamics modeling to understand overdose bystander behavior in the context of Connecticut\u2019s Good Samaritan Laws and identify effective policy options","volume":"21","author":"Thompson","year":"2024","journal-title":"Harm Reduct J"},{"key":"2025120413253228000_15.11.e102796.47","unstructured":"Ventana Systems Inc . Vensim. 2024."},{"key":"2025120413253228000_15.11.e102796.48","unstructured":"U.S. Food and Drug Administration . What is digital health, 2020. Available: https:\/\/www.fda.gov\/medical-devices\/digital-health-center-excellence\/what-digital-health [Accessed 18 Feb 2025]."},{"key":"2025120413253228000_15.11.e102796.49","unstructured":"U.S. Food and Drug Administration . Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence-Enabled Device Software Functions, 2024. Available: https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/marketing-submission-recommendations-predetermined-change-control-plan-artificial-intelligence [Accessed 29 Sep 2025]."},{"key":"2025120413253228000_15.11.e102796.50","unstructured":"Yale University Human Research Protection Program (HRPP) . Yale University Human Research Protection Program (HRPP) policy and standard operating procedure manual, 2023. Available: https:\/\/your.yale.edu\/sites\/default\/files\/files\/ResearchSupport\/HRPP_Policy_and_Standard_Operating_Procedure_Manual_20230724.pdf [Accessed 18 Feb 2025]."},{"key":"2025120413253228000_15.11.e102796.51","unstructured":"National Institute on Drug Abuse . Regulations, policies, and guidance, 2016. Available: https:\/\/nida.nih.gov\/research\/clinical-research\/regulations-policies-guidance [Accessed 18 Feb 2025]."},{"key":"2025120413253228000_15.11.e102796.52","unstructured":"National Institutes of Health . Clinical Trials Stewardship, 2017. Available: https:\/\/nida.nih.gov\/research\/nih-policies-guidance\/clinical-trials-stewardship#GCP [Accessed 18 Feb 2025]."}],"container-title":["BMJ Open"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjopen-2025-102796","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,4]],"date-time":"2025-12-04T21:26:03Z","timestamp":1764883563000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjopen.bmj.com\/lookup\/doi\/10.1136\/bmjopen-2025-102796"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":52,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,4]]},"published-print":{"date-parts":[[2025,11]]}},"alternative-id":["10.1136\/bmjopen-2025-102796"],"URL":"https:\/\/doi.org\/10.1136\/bmjopen-2025-102796","relation":{},"ISSN":["2044-6055","2044-6055"],"issn-type":[{"type":"print","value":"2044-6055"},{"type":"electronic","value":"2044-6055"}],"subject":[],"published":{"date-parts":[[2025,11]]}}}